EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Prior Sales
Prior Sales
The following table summarizes details of each class of securities of the Company that is outstanding but not listed or quoted on a marketplace, issued by the Company during the most recently completed financial year:
| Date of Issuance/Grant | Type of Security | Number of Securities Issued | Issue/Exercise Price |
|---|---|---|---|
| May 13, 2024 | Options | 1,456,880 | CDN$3.96 |
| May 28, 2024 | Options | 50,000 | CDN$3.82 |
| August 9, 2024 | Options | 82,000 | CDN$3.48 |
| October 31, 2024 | Series 1 PreferredShares | 8,905,638 | CDN$5.00 |
| November 25, 2024 | Options | 350,000 | CDN$4.91 |
| December 10, 2024 | Options | 90,000 | CDN$3.96 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.